A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
Latest Information Update: 15 May 2024
At a glance
- Drugs Selumetinib (Primary)
- Indications Neurofibromatosis 1; Plexiform neurofibroma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 08 May 2024 Planned End Date changed from 31 Oct 2023 to 31 Aug 2026.
- 08 May 2024 Status has been changed to active, no longer recruiting.
- 23 Sep 2022 Planned End Date changed from 8 Oct 2026 to 31 Oct 2023.